Patricia Weiser

1 week ago | managedhealthcareexecutive.com | Patricia Weiser

Patients with advanced non–small cell lung cancer (NSCLC) experience markedly different survival outcomes and treatment costs depending on their tumor biomarker status, according to a new study led by Juanyi Tan, MPH. The findings, published earlier this month in JAMA Network Open, highlight the need for better and more affordable treatment options for cases without biomarkers. Lung cancer is the leading cause of cancer death in the U.S., and most cases are diagnosed at an advanced stage.

2 weeks ago | singlecare.com | Patricia Weiser

Key takeaways Encourage patients to start planning at least four to six weeks before summer travel to allow enough time for vaccines, refills, and documentation, especially if traveling abroad. Counsel patients on properly storing medications and on adjusting dosing schedules across time zones. Recommend a basic health kit stocked with OTC essentials like pain relievers, sunscreen, and insect repellent.

2 weeks ago | managedhealthcareexecutive.com | Patricia Weiser

Adding Opdivo (nivolumab) to chemotherapy before surgery significantly improves long-term overall survival compared to chemotherapy alone in patients with operable non-small cell lung cancer (NSCLC), according to a five-year analysis of a phase 3 trial. The results were published June 2 in The New England Journal of Medicineand presented at the annual meeting of the American Society of Clinical Oncology (ASCO). The research, led by Patrick M.

3 weeks ago | managedhealthcareexecutive.com | Patricia Weiser

Tracking how symptoms change over time in people with non-small cell lung cancer (NSCLC) may help predict survival and improve patient-centered care, according to new research out of the University of North Carolina. The study, published late last month in Clinical Cancer Research, found that patient-reported outcomes (PROs) can offer important insights into disease progression and treatment response when analyzed over time.

1 month ago | managedhealthcareexecutive.com | Patricia Weiser

The FDA has granted Mesoblast’s stem cell therapy, Ryoncil (remestemcel-L), seven years of orphan drug exclusivity for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD) in children ages 2 months and older, the company announced May 14. The exclusivity designation means the FDA will not approve another mesenchymal stromal or stem cell product for the same condition until 2032.